Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10672
Title: Clinical use of therapies targeting tumor vasculature and stroma.
Authors: Davis, Ian D;Desai, Jayesh
Affiliation: Austin Hospital and Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia. Ian.Davis@ludwig.edu.au
Issue Date: 1-Sep-2008
Citation: Current Cancer Drug Targets; 8(6): 498-508
Abstract: Many recent advances in cancer therapy have been based on an understanding of the basic biology of the cancer cell itself, particularly with respect to abnormalities in various signalling pathways. It has become increasingly apparent that malignant cells exist in a complex cellular and extracellular microenvironment, which can play key roles in the initiation and maintenance of the malignant phenotype. These interactions can provide therapeutic targets that are now being exploited in the clinic. Much attention has been paid to agents that disrupt angiogenesis or existing tumor vasculature, however other cellular and non-cellular components of the tumor mass mediate critical functions and can also be useful treatment targets. Treatments directed at these interactions bring new challenges in terms of how best to develop these strategies, and require approaches that differ in many ways from conventional anticancer therapies.
Internal ID Number: 18781896
URI: http://ahro.austin.org.au/austinjspui/handle/1/10672
URL: http://www.ncbi.nlm.nih.gov/pubmed/18781896
Type: Journal Article
Subjects: Angiogenesis Inhibitors.pharmacology
Humans
Neoplasms.blood supply.drug therapy.pathology
Neovascularization, Pathologic.drug therapy
Stromal Cells.pathology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.